GlassScriptPhysician profile
Sricharan Moturi
NPI 1346459351
$82,274.29
in general payments reported to CMS, 2019-2025
29 companies · $14.36 in 2025
The $14.36 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,674 · 2021: $6,782 · 2022: $10K · 2023: $26K · 2024: $19K · 2025: $14.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Honoraria: $8,050 · Travel and Lodging: $2,152 · Food and Beverage: $2,086 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,950.00 |
| Honoraria | $8,050.00 |
| Travel and Lodging | $2,152.28 |
| Food and Beverage | $2,085.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,132.98 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $22,788.49 | 2021-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $17,451.26 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Takeda Pharmaceuticals U.S.A., INC. | $5,547.14 | 2019-2023 | Trintellix |
| Neos Therapeutics, LP | $1,420.17 | 2019-2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $1,181.93 | 2019-2022 | |
| Aytu Biopharma, INC. | $1,022.38 | 2021 | |
| Jazz Pharmaceuticals INC. | $813.07 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $675.70 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $520.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $358.39 | 2019-2022 | |
| Alkermes, INC. | $302.71 | 2019-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $165.88 | 2022-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.80 | 2023 | |
| Indivior INC. | $117.55 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $105.51 | 2019 | |
| Harmony Biosciences LLC | $105.50 | 2020-2022 | |
| Noven Therapeutics, LLC | $82.53 | 2020-2021 | |
| Axsome Therapeutics, INC. | $69.71 | 2022-2024 | Auvelity |
| Adlon Therapeutics L.P. | $58.85 | 2021 | |
| Lundbeck LLC | $50.01 | 2019 | |
| Corium, LLC | $29.57 | 2022-2023 | Azstarys |
| Avadel Cns Pharmaceuticals, LLC | $23.25 | 2024 | Lumryz |
| Tempus Ai, INC | $21.03 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.24 | 2023 | Horizant |
| Esperion Therapeutics, INC. | $17.94 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $17.81 | 2019 | |
| Neurocrine Biosciences, INC. | $17.60 | 2023 | Ingrezza |
| Vertical Pharmaceuticals, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sricharan Moturi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.